KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Stopped Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in the study.

Conditions

• Small-cell Lung Cancer
• Small Cell Lung Carcinoma
• Small Cell Lung Cancer Extensive Stage
• Small Cell Lung Cancer Recurrent

Interventions

• DRUG: KRT-232

Sponsor

Kartos Therapeutics, Inc.